Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valsartan effect on glycemic control in T2DM
NCT04707508Phase 4Completed
- Sponsor
- Nantou Christian Hospital
- Start
- Dec 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of valsartan in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Nantou Christian Hospital. Primary endpoint: Serum glycosylated hemoglobin A1c at 24 weeks. Started Dec 2017; status: completed.
02
Drugs
valsartan
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04707508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04707508.